# EDGAR Filing Document

**Accession Number:** 0000724445
**File Stem:** 0001104659-26-047711
**Filing Date:** 2026-4
**Character Count:** 7228
**Document Hash:** d71f7423c66e8b0bdfcb7917c8412651
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-047711.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001104659-26-047711

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260417

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BURZYNSKI RESEARCH INSTITUTE INC
- **CENTRAL INDEX KEY:** 0000724445
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 760136810
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0228

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-23425
- **FILM NUMBER:** 26888845

**BUSINESS ADDRESS:**
- **STREET 1:** 12000 RICHMOND AVE
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77082
- **BUSINESS PHONE:** (713) 335-5697

**MAIL ADDRESS:**
- **STREET 1:** 9432 KATY FREEWAY
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77055

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**April 17, 2026**

**Date of Report (Date of earliest event reported)**

**Burzynski Research Institute, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-23425** | **76-0136810** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission<br> File Number)** | **(I.R.S. Employer<br> Identification Number)** |

---

**9432 Katy Freeway, Suite 200, Houston, TX 77055**

**(Address of principal executive offices)**

**(713) 335-5697**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| None | BZYR | None |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§240.12b–2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On April 16, 2026, Patryk P. Goscianski resigned as the Chief Financial Officer (principal financial officer and principal accounting officer) (the "CFO") and Secretary of Burzynski Research Institute, Inc. (the "Company"), effective on April 17, 2026.

Mr. Goscianski's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. A copy of Mr. Goscianski's resignation letter is filed as Exhibit 17.1 to this Current Report on Form 8-K.

Effective on April 17, 2026, the Board of Directors appointed Stanislaw R. Burzynski, M.D., Ph.D. as the Company's Chief Financial Officer (principal financial officer and principal accounting officer) and Secretary. Dr. Burzynski currently serves as the Company's President, Chairman of the Board of Directors and principal executive officer, and as a result of this appointment, Dr. Burzynski will serve as both the Company's principal executive officer and principal financial officer.

Dr. Burzynski will not receive any additional compensation in connection with this appointment.

Dr. Burzynski, 83, is the Company's controlling stockholder and is a party to the New License Agreement, the Amended and Restated Research Funding Agreement and the Royalty Agreement with the Company as described in the Company's Annual Report on Form 10-K for the year-ended February 28, 2025, which descriptions are incorporated herein by reference. Dr. Burzynski is the father of Gregory S. Burzynski and step-father of Monika Szopa-Paszkowiski, the other two members of the Company's Board of Directors. Dr. Burzynski's biographical history is set forth in the Company's Annual Report on Form 10-K for the year-ended February 28, 2025. Other than these three agreements, there are no related party transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K in connection with Dr. Burzynski's appointment as CFO and Secretary.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

[Exhibit 17.1](tm2612461d1_ex17-1.htm) [Resignation Letter of Patryk P. Goscianski, dated April 16, 2026.](tm2612461d1_ex17-1.htm) <br> 104 Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: April 23, 2026 | **BURZYNSKI RESEARCH INSTITUTE, INC.** | **BURZYNSKI RESEARCH INSTITUTE, INC.** |
|  | By: | /s/ Stanislaw R. Burzynski |
|  |  | Stanislaw R. Burzynski |
|  |  | President, Chief Financial Officer, Secretary and Chairman of the Board of Directors |

---

## Exhibit 17.1

**Exhibit 17.1**

April 16, 2026

Burzynski Research Institute, Inc.

9432 Katy Freeway

Houston, TX 77055

RE: Resignation <br>TO: Burzynski Research Institute, Inc and its Directors and Officers,

With this letter, I hereby submit my resignation as Chief Financial Officer and Secretary of Burzynski Research Institute, Inc. due to personal reasons and effective as of April 17, 2026.

I am thankful for the opportunity to serve Burzynski Research Institute, Inc. for over past 14 years, and I offer my best wishes for its continued success.

Sincerely,

/s/ Patryk P. Goscianski

Patryk P. Goscianski, MBA

CC:

Stanislaw R. Burzynski, M.D., Ph.D.

Gregory Burzynski, M.D.

Monika Szopa-Paszkowiak